구조모아 (StructureMoa)항암 chemical structure spider web
방문타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-6 · 마지막 9월 2일
현재 선택: 1개 · 임상 갱신 필요 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | |
|---|---|
Overview Program | Trastuzumab emtansine (T-DM1) |
Overview Company | Roche / Genentech |
Overview Modality | ADC |
Overview Target | HER2 |
Overview Indication | Unrespectable Locally Advanced and or Metastatic HER2 Positive Breast Cancer Participants |
Overview Phase | PHASE_3 |
Overview Status | RECRUITING |
Overview Content status | Standard Database |
Overview Data Confidence | Data Confidence · Medium |
Overview Development Signal | Development Signal · Emerging |
Overview Approval status | Investigational |
Technology Payload | DM1 via butelase-1 with ABD fusion for pote |
Technology Linker | cleavable peptide linker and a topoisomerase I payload with byst |
MoA Mechanism | targeting human epidermal growth factor receptor |
MoA Biomarker | HER2-positive |
PK/PD Half-life | 4 h |
PK/PD Species | Mouse |
PK/PD Animal (cat.) | Mouse, In vitro |
PK/PD Experiment | tumor growth inhibition |
Toxicology Species | Mouse |
Toxicology Animal (cat.) | Mouse, In vitro |
Toxicology Major finding | Interstitial lung disease was observed for both agents |
Clinical Safety signal | Interstitial lung disease was observed for both agents |
Clinical Selected reported efficacy | ORR 69.7% |
Clinical Reported ORR | 69.7% |
Clinical Reported PFS | 17.8 |
Clinical Reported OS | 39.2 |
Clinical Result source | ClinicalTrials.gov NCT03523585 |
Clinical Program phase | PHASE_3 |
Clinical Trial ref | NCT03523585 |
타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-6 · 마지막 9월 2일
현재 선택: 1개 · 임상 갱신 필요 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | |
|---|---|
Overview Program | Trastuzumab emtansine (T-DM1) |
Overview Company | Roche / Genentech |
Overview Modality | ADC |
Overview Target | HER2 |
Overview Indication | Unrespectable Locally Advanced and or Metastatic HER2 Positive Breast Cancer Participants |
Overview Phase | PHASE_3 |
Overview Status | RECRUITING |
Overview Content status | Standard Database |
Overview Data Confidence | Data Confidence · Medium |
Overview Development Signal | Development Signal · Emerging |
Overview Approval status | Investigational |
Technology Payload | DM1 via butelase-1 with ABD fusion for pote |
Technology Linker | cleavable peptide linker and a topoisomerase I payload with byst |
MoA Mechanism | targeting human epidermal growth factor receptor |
MoA Biomarker | HER2-positive |
PK/PD Half-life | 4 h |
PK/PD Species | Mouse |
PK/PD Animal (cat.) | Mouse, In vitro |
PK/PD Experiment | tumor growth inhibition |
Toxicology Species | Mouse |
Toxicology Animal (cat.) | Mouse, In vitro |
Toxicology Major finding | Interstitial lung disease was observed for both agents |
Clinical Safety signal | Interstitial lung disease was observed for both agents |
Clinical Selected reported efficacy | ORR 69.7% |
Clinical Reported ORR | 69.7% |
Clinical Reported PFS | 17.8 |
Clinical Reported OS | 39.2 |
Clinical Result source | ClinicalTrials.gov NCT03523585 |
Clinical Program phase | PHASE_3 |
Clinical Trial ref | NCT03523585 |
추천 비교
추천 비교